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    Endo-α-N-acetylgalactosaminidase catalyzes the release of Galβ1-3GalNAc from the core 
1-type O-glycan (Galβ1-3GalNAcα1-Ser/Thr) of mucin glycoproteins and synthetic p-nitrophenyl 
(pNP) α-linked substrates. Here, we report the enzymatic syntheses of core 1 
disaccharide-containing glycopeptides using the transglycosylation activity of 
endo-α-N-acetylgalactosaminidase (EngBF) from Bifidobacterium longum. The enzyme directly 
transferred Galβ1-3GalNAc to serine or threonine residues of bioactive peptides such as PAMP-12, 
bradykinin, peptide-T and MUC1a when Galβ1-3GalNAcα1-pNP was used as a donor substrate. 
The enzyme was also found to catalyze the reverse-hydrolysis reaction. EngBF synthesized the core 
1 disaccharide-containing oligosaccharides when the enzyme was incubated with either glucose or 
lactose and Galβ1-3GalNAc prepared from porcine gastric mucin using bifidobacterial cells 
expressing endo-α-N-acetylgalactosaminidase. Synthesized oligosaccharides are promising 







    Glycosidases are divided into two types based on their catalytic mechanisms: retaining and 
inverting glycosidases. Most of the retaining glycosidases show transglycosylation activity in 
addition to hydrolysis activity. The transglycosylation reaction is recognized as a part of the 
hydrolysis reaction in which the water molecule is replaced with a compound containing a 
hydroxyl-group. In contrast to many examples of transglycosylation by exoglycosidases, there is a 
paucity of information describing transglycosylation by endoglycosidases acting on complex 
carbohydrates. Transglycosylation activities of endoglycosidases acting on complex carbohydrates 
are potentially very powerful tools for the syntheses of a wide variety of glycosyl compounds. This is 
because endoglycosidases are able to conjugate oligosaccharides en bloc to acceptors. Moreover 
enzymatic remodeling of O- and N-glycans in glycoproteins using endoglycosidases is one of the 
most promising approaches in the production of homogeneous glycoproteins [1]. We have reported 
that several microbial endoglycosidases showed strong transglycosylation activities and some of 
these enzymes could be applicable to the syntheses of bioactive glycoconjugates [2-7]. 
    Recently, we identified the gene engBF encoding an endo-α-N-acetylgalactosaminidase from 
Bifidobacterium longum JCM1217, which belongs to a novel glycoside hydrolase family GH101 [8]. 
EngBF preferably released Galβ1-3GalNAc from the core 1-type O-glycan, also referred to as the 
Thomsen-Friedenreich antigen (T-antigen), of mucin glycoproteins. EngBF also showed 
transglycosylation activity of the released disaccharide to other mono- and disaccharides.  
    In the present paper, we report syntheses of the core 1 disaccharide-containing glycopeptides 
using the transglycosylation activity of EngBF. Furthermore, EngBF was found to catalyze the 
reverse-hydrolysis reaction, and using this activity we synthesized oligosaccharides without a 
synthetic donor substrate. Such an approach may be useful in the production of bifidus factors, the 
prebiotics for bifidobacteria.  
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Materials and methods 
Peptides 
    PAMP-12, bradykinin and peptide-T were purchased from the Peptide Institute Inc., Japan. 
MUC1a and PAMP-12(S11T) were synthesized by Sigma Genosys (Sigma-Aldrich Japan). The 
peptide sequences are shown in Table 1. 
 
Enzyme preparation 
    The six histidine-tagged EngBF was expressed in E. coli BL21(λDE3) and purified by affinity 
chromatography and gel filtration as previously described [8]. The purified recombinant EngBF 
showed no protease and exoglycosidase activities. 
 
Transglycosylation and reverse-hydrolysis reaction of EngBF 
    For transglycosylation to various monosaccharides or amino acids as acceptors, 5 mM 
Galβ1-3GalNAcα1-pNP (Toronto Research Chemicals, Canada) and 500 mM of the acceptor 
substrate were incubated with 80 milliunits of EngBF in 50 mM sodium acetate buffer (pH 6.0) at 37 
°C for an appropriate period. For transglycosylation to peptides, 5 mM Galβ1-3GalNAcα1-pNP and 
15 mM peptide were incubated with 100 milliunits of EngBF in 50 mM sodium acetate buffer (pH 
6.0) under the same conditions. For the reverse-hydrolysis reaction, 1 M glucose and 100 mM 
Galβ1-3GalNAc were incubated with 0.8 units of EngBF in 50mM sodium acetate buffer (pH 6.0) at 
37 °C for an appropriate period.  
 
High-performance Liquid Chromatography 
    Normal phase high-performance liquid chromatography (HPLC) was performed using a 
TSK-Gel Amide-80 column (4.6 × 250 mm, Tosoh, Japan). Elution was carried out with 
acetonitrile:water (3:1, by volume) as the solvent at a flow rate of 1.0 ml/min at 40 °C and detection 
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of GlcNAc-containing sugars and p-nitrophenol was monitored by the absorbance at 214 nm. 
Reversed phase HPLC was performed using a Cosmosil 5C18-AR-II column (4.6 × 250 mm 
Nacalai Tesque, Japan). Elution was carried out with a linear gradient of acetonitrile containing 0.1% 
trifluoroacetic acid at a flow rate of 1.0 ml/min at 40 °C and detection of compounds was monitored 
by absorbance at 214 or 280 nm. 
 
Mass spectrometry 
    For glycopeptides, matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS) analyses were carried out using a Bruker Daltonics Autoflex-G system (MA, 
USA) with a 337-nm nitrogen laser, using the positive-ion mode, the reflectron mode and external 
calibration with PEG. The sample was dissolved in ethanol at a concentration of 1 mg/ml. An 
α-cyano-4-hydroxycinnamic acid solution (25 mg/ml in acetonitrile:0.1% TFA = 3:1, by volume) 
was used as the matrix. Half-a-microliter of the mixture of these solutions (matrix:sample = 4:1, by 
volume) was placed on the AnchorChip target (Bruker, Germany). During the measurement, 30 laser 
shots were used and the data of the mass spectra were collected at different positions of the 
crystallized sample spot. For oligosaccharides, MALDI-TOF-MS analyses were carried out using a 
Voyager-DE STR (Applied Biosystems). Samples were analyzed in the positive ion mode using 
α-cyano-4-hydroxycinnamic acid, 2,5-dihydroxybenzoic acid or 
2’,4’,6’-trihydroxyacetophenonen-hydorate as the matrix. 
 
Thin layer chromatography  
    Thin layer chromatography (TLC) was performed using silica-gel TLC plates (Merck 5553) 
with 1-butanol:acetic acid:water = 2:1:1 (by volume) as the developing solvent. For separation of 
Galβ1-3GalNAc and Galβ1-3GlcNAc, 1-propanol:0.2% CaCl2 = 11:2 (by volume) was used. The 
diphenylamine aniline reagent was used to visualize the sugars [9]. 
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Preparation of Galβ1-3GalNAc from porcine gastric mucin 
    Bifidobacterium bifidum ATCC29521 was cultured in GAM broth (Nissui Pharmaceutical, 
Japan) containing 0.5% porcine gastric mucin (Sigma-Aldrich) for 16 h at 37 °C under anaerobic 
conditions using Anaeropack (Mitsubishi Chemical, Japan). For preparation of Galβ1-3GalNAc, 5 g 
porcine gastric mucin was incubated with a cell suspension of bifidobacteria in 50 mM sodium 
acetate buffer (pH 6.0) for 16 h at 37 °C. The supernatant was precipitated twice with 90% ethanol to 
remove proteins, concentrated and subsequently applied on to a Sephadex G-15 gel filtration column 
(2 × 50 cm, GE Healthcare). The disaccharide-containing fraction was concentrated and subjected to 
normal phase HPLC with acetonitrile:water = 4:1 (by volume) as a solvent to separate 
Galβ1-3GalNAc and Galβ1-3GlcNAc. Sugar compositions were confirmed after the treatment with 
β1,3-specific galactosidase from Xanthomonas manihotis (Calbiochem, CA). 
 
Results 
Transglycosylation of Galβ1-3GalNAc to serine and threonine 
    We previously demonstrated that EngBF could transfer the disaccharide Galβ1-3GalNAc from 
a donor substrate Galβ1-3GalNAcα1-pNP to acceptors such as 1-alkanols and mono- and 
disaccharides [8]. To apply this enzyme for syntheses of O-glycan-containing glycopeptides, we first 
examined whether EngBF could transfer the disaccharide to a hydroxyl group of a free threonine or 
serine. Galβ1-3GalNAcα1-pNP and threonine were incubated with the recombinant EngBF and the 
reaction mixture was analyzed by normal phase HPLC. The HPLC results showed a new peak 
appearing at the retention time (RT) of 32.25 min. This peak was considered to be a 
transglycosylation product (Fig. 1, middle panel). A new peak with a RT of 37.09 min was detected 
when serine was used as an acceptor (bottom panel). No new peaks were observed when no acceptor 
was present in the reaction mixture (upper panel). These two products were isolated and analyzed by 
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ESI-MS to determine their molecular masses. On the former product, a major mass ion peak was 
detected at m/z 507.75, which corresponded to the sodium adduct of Galβ1-3GalNAcα1-Thr 
(theoretical mass, 484.20). Similarly, on the latter product, a peak at m/z 493.72 was detected for the 
sodium adduct of Galβ1-3GalNAcα1-Ser (theoretical mass, 470.17). These isolated products were 
completely re-hydrolyzed by EngBF, indicating that these compounds were the transglycosylation 
products (data not shown).  
 
Enzymatic syntheses of mucin-type glycopeptides by EngBF 
    We subsequently examined to determine whether EngBF could transfer the disaccharide to Ser 
or Thr residues in peptides. We selected PAMP-12 (FRKKWNKWALSR) as an acceptor, which is a 
potent hypotensive peptide processed from the adrenomedullin precursor and possess one Ser 
residue at the penultimate position in the sequence [10]. Incubation of PAMP-12 with EngBF in the 
presence of the donor substrate Galβ1-3GalNAcα1-pNP gave rise to two new peaks in the reversed 
phase HPLC chromatogram (Fig. 2A, bottom chart). The RT of the two new peaks were 52.2 and 
61.6 min. The new peak eluting at a later RT value corresponded to p-nitrophenol released from the 
donor substrate. Consequently, the peak that eluted at an earlier RT value was assumed to represent 
the transglycosylation peptide product because such a product was not detected in the reaction 
mixture using an inactivated enzyme control (Fig. 2A, top chart). We analyzed this peak by 
MALDI-TOF-MS. The singly protonated mass ion peak at m/z 1984.68 corresponded to 
Galβ1-3GalNAc-attached PAMP-12 (Fig. 2B), indicating that it was the transglycosylation product 
formed by EngBF. The product was completely re-hydrolyzed by EngBF (data not shown), 
confirming that the disaccharide from the donor substrate was transferred to the hydroxyl group of 
the Ser residue in PAMP-12 via an α-linkage.  
    Furthermore, to examine whether EngBF could transfer the disaccharide to a Thr residue in 
peptides, we used a mutant PAMP-12 as an acceptor, in which the Ser residue was changed to a Thr 
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(PAMP-12(S11T)). Similarly in the case of PAMP-12, a new peak was observed in the reversed 
phase HPLC chromatogram. This peak was identified to be a transglycosylation product by 
MALDI-TOF-MS analysis (m/z 1999.08 for (M+H)+) (Fig. 2C). The amount of the 
transglycosylation product was about one-third when compared to the amount produced using 
PAMP-12 as the acceptor.  
    We further attempted to transfer Galβ1-3GalNAc to various Ser/Thr-containing peptides. The 
results of these analyses are summarized in Table 1. Bradykinin (RPPGFSPFR) is a bioactive 
peptide inhibitor for the angiotensin-converting enzyme, and therefore a potent hypotensive drug 
[11]. This peptide has a single Ser residue located four residues from the C-terminus. A 
transglycosylation product toward bradykinin was found by analysis using reversed phase HPLC, 
but the efficiency of the transglycosylation was about one-tenth of the observed transglycosylation of 
PAMP-12. MUC1a (AHGVTSAPDTR) is a part of the repetitive icosapeptides 
(AHGVTSAPDTRPAPGSTAPP) of a mucin MUC1 that is expressed by the normal mammary 
gland, stomach and pancreas, and is also highly expressed by cancer cells [12]. MUC1a contains one 
Ser and two Thr residues: i.e., three transglycosylation sites are available. However, only a single 
major peak in the HPLC chromatogram was observed and assumed to be a transglycosylation 
product of MUC1a with a single Galβ1-3GalNAc. Peptide T (ASTTTNYT) is a potent peptide for 
anti-HIV infection, having one Ser and four Thr residues [13]. The analysis of the transglycosylation 
products showed that a single major and two minor peaks were observed in the HPLC 
chromatogram. These products were isolated and analyzed by MALDI-TOF-MS and were found to 
be modified by one disaccharide. 
 
Preparation of Galβ1-3GalNAc from porcine gastric mucin using bifidobacterial cells 
    To examine the reverse-hydrolysis reaction of EngBF, we first attempted to prepare the free 
disaccharide Galβ1-3GalNAc from porcine gastric mucin using the recombinant EngBF. However, 
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only a slight amount of released Galβ1-3GalNAc was observed even in the presence of sialidase and 
α-N-acetylglucosaminidase [14]. This observation may be due to the modification of the core 1-type 
O-glycan (Galβ1-3GalNAcα1-) by several other sugars such as α-Fuc, β-Gal and β-GlcNAc. We 
then used bifidobacterial cells to prepare the disaccharide because bifidobacteria possess many types 
of glycosidases. Among the various bifidobacteria, we found that B. bifidum ATCC29521 could 
effectively release the disaccharide from porcine gastric mucin as well as a few monosaccharides 
such as Gal and sialic acid (Fig. 3). We purified the released disaccharide and confirmed that this 
disaccharide was Galβ1-3GalNAc by treatment with β1,3-specific galactosidase from X. manihotis 
and MALDI-TOF-MS (m/z 407.45 for (M+Na)+). Finally, approximately 120 mg of the pure 
Galβ1-3GalNAc was obtained from 5 g of porcine gastric mucin. 
 
Reverse-hydrolysis reaction of EngBF 
    To assess the reverse-hydrolysis reaction of EngBF, 100 mM Galβ1-3GalNAc and 1 M glucose 
were incubated with active or heat-inactivated EngBF. After incubation for 3 h at 37 °C, the reaction 
mixtures were analyzed by normal phase HPLC. In the presence of the active enzyme, a broad new 
peak was found at a RT of 28 min (Fig. 4A, top chart), which was not observed in the chromatogram 
of the reaction mixture containing heat-inactivated enzyme (data not shown). The reaction was 
subsequently lengthened to 120 h. The peak of the new product reached a maximum after 72 h 
incubation, and then slightly decreased until 120 h (Fig. 4A). We collected the fractions 
corresponding to the new peak from the 72-h reaction mixture and analyzed this species by TLC (Fig. 
4B, lane 4). The analysis showed that this compound had the same mobility as the authentic 
Galβ1-3GalNAcα1-Glc prepared by the transglycosylation reaction using Galβ1-3GalNAcα1-pNP 
and Glc (lane 3) [8]. The product was completely hydrolyzed to Galβ1-3GalNAc and Glc after 
incubating with EngBF (lane 5). MALDI-TOF-MS analysis of this new product detected mass ion 
peaks at m/z 569.18 for (M+Na)+ and m/z 585.13 for (M+K)+, confirming that the product was the 
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trisaccharide Galβ1-3GalNAcα1-Glc (theoretical mass, 545.49) (Fig. 4B). The yield of the 
trisaccharide at 72 h incubation based on the amount of the substrate Galβ1-3GalNAc was estimated 
to be 10.7 % by the peak areas of HPLC chromatogram. Furthermore, when 100 mM 
Galβ1-3GalNAc and 0.5 M lactose were incubated with EngBF, the peak representing the 
reverse-hydrolysis product was found at a RT of 47 min using normal phase HPLC. 
MALDI-TOF-MS analysis gave a mass ion peak at m/z 730.99 (M+Na)+ and the product was 
assumed to be Galβ1-3GalNAcα1-lactose (theoretical mass, 707.63). The yield at 72 h incubation 
was approximately 2 %. 
 
Discussion 
    In mammalian cells, the biosyntheses of mucin-type oligosaccharides are initiated by 
attachment of α-GalNAc to Ser/Thr residues of polypeptides by 
polypeptide:N-acetylgalactosaminyltransferases located on the luminal side of the Golgi apparatus. 
Following this initial attachment, other glycosyltransferases are used for elongation of the sugar 
chains. In lower eukaryotes and prokaryotes, this kind of protein modification is missing. Recently, 
genetically engineered yeast Saccharomyces cerevisiae capable of producing core 1 
O-glycan-containing peptides was developed [15]. In this strain, human 
polypeptide:N-acetylgalactosaminyltransferase-1, Drosophila melanogaster core 1 
β1,3-galactosyltransferase and several other genes were introduced. However, this approach may be 
complicated because there are twenty polypeptide:N-acetylgalactosaminyltransferases with different 
acceptor specificities to be selected [16]. Chemical synthesis of these glycopeptides in vitro is not 
easy, because this synthesis needs a multistep process. In this paper, we employed the 
transglycosylation activity of EngBF from B. longum to achieve a one-step synthesis of the core 1 
disaccharide-containing glycopeptides. Transglycosylation of Galβ1-3GalNAc to a Ser-containing 
hexapeptide has already been reported using a similar enzyme, endo-α-N-acetylgalactosaminidase S 
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partially purified from the culture supernatant of Streptomyces sp. OH-11242 [17], though 
transglycosylation to Thr residues was not reported. In this study, EngBF was shown to have the 
ability to transfer Galβ1-3GalNAc to both Ser and Thr residues using the bioactive peptide 
PAMP-12 and its derivative. This enzyme seems to prefer Ser residue rather than Thr residue as an 
acceptor, though further experiments are necessary to conclude. We also showed that other three 
bioactive peptides could be acceptors for this enzyme. Therefore, a simple method to synthesize core 
1 O-glycan-containing peptides using EngBF with broad acceptor specificity has been presented. 
The addition of sugar chain(s) to bioactive peptides may furnish some positive effects, such as 
increasing resistance to proteases, increasing stability and extending the half-life in the bloodstream. 
In the case of the mucin repetitive peptide MUC1a, sugar-conjugate could be a promising anti-tumor 
vaccine for blocking metastasis [18]. Enzymatic transglycosylation require donor substrates such as 
synthetic substrates which are usually expensive. Recently, an efficient chemical synthesis of 
α-GalNAc glycosides using the di-tert-butylsylene-directed method was developed [19-21] and this 
method is expected to lower the cost of production of the donor substrate. Although this enzymatic 
approach present in this study provides a simple and powerful tool for syntheses of O-glycopeptides, 
it is currently not easy to control the number and position of the disaccharide modification on the 
peptides with multiple Ser/Thr residues. Incomplete glycosylation may be due to the low efficiency 
of the transglycosylation by EngBF. The improvement of the transglycosylation efficiency of EngBF 
by mutagenesis and/or the use of higher amount of the donor substrate may overcome the weakness 
of this approach. 
    We also achieved the syntheses of oligosaccharides by the reverse-hydrolysis reaction of 
EngBF, which does not require donor substrates such as Galβ1-3GalNAcα1-pNP. Since the 
synthesized oligosaccharides are degraded by endo-α-N-acetylgalactosaminidases that are widely 
distributed in the Bifidobacterium species, these oligosaccharides could be assimilated by those 
bacteria and may function as a bifidus factor. We have previously described that bifidobacteria are 
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able to incorporate the Galβ1-3GalNAc into the cells through an ABC-type transporter specific for 
Galβ1-3GalNAc and Galβ1-3GlcNAc [22, 23]. The disaccharide is phosphorolyzed by intracellular 
Galβ1-3GalNAc/Galβ1-3GlcNAc phosphorylase to further degradation [24-26]. Since the 
β1,3-linked Gal is hardly hydrolyzed by enterobacterial β-galactosidases, Galβ1-3GalNAc may be 
specifically utilized by bifidobacteria. 
    The analysis of the crystal of EngBF has been completed [27]. Using the structural information 
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Fig. 1 Transglycosylation of Galβ1-3GalNAc to free threonine and serine by EngBF. The donor 
substrate Galβ1-3GalNAcα1-pNP was incubated with EngBF in the presence or absence of 
threonine or serine and analyzed by normal phase HPLC. Upper panel, no amino acid was added; 
middle panel, threonine was added as an acceptor; lower panel, serine was added as an acceptor. 
New peaks appeared at 32.25 min in the middle panel and at 37.09 min in the bottom panel. S, 
Galβ1-3GalNAcα1-pNP; NP, p-nitrophenol; DS, Galβ1-3GalNAc.  
 
Fig. 2 Transglycosylation of Galβ1-3GalNAc to PAMP-12 by EngBF. (A) Reversed phase HPLC 
chromatograms of the transglycosylation reaction mixtures containing Galβ1-3GalNAcα1-pNP and 
PAMP-12 with heat-inactivated (upper chart) or active (bottom chart) EngBF. S, 
Galβ1-3GalNAcα1-pNP; NP, p-nitrophenol; TG, possible transglycosylation product. (B) 
MALDI-TOF-MS analysis of the PAMP-12 transglycosylation product. The theoretical mass of 
Galβ1-3GalNAc-attached PAMP-12 is 1984.24. (C) MALDI-TOF-MS analysis of the 
PAMP-12(S11T) transglycosylation product. The theoretical mass of Galβ1-3GalNAc-attached 
PAMP-12(S11T) is 1998.26. 
 
Fig. 3 Production of Galβ1-3GalNAc from porcine gastric mucin using the cells of Bifidobacterium 
bifidum ATCC29521. The cells grown in the GAM medium were washed with phosphate buffered 
saline and incubated with porcine gastric mucin. The supernatant of the reaction mixture was 
precipitated by ethanol to remove proteins and then analyzed by TLC. Lane 1, bifidobacterial cells 
only; lane 2, mucin incubated with bifidobacterial cells; lane 3, mucin only; lane 4, standard Gal; 
lane 5, standard Galβ1-3GalNAc.  
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Fig. 4 Reverse-hydrolysis reaction of EngBF. (A) Normal phase HPLC chromatogram of the 
reverse-hydrolysis reaction product. Galβ1-3GalNAc and glucose were incubated with EngBF for 
indicated periods and then analyzed by HPLC. A new product (P) appeared with a RT of 28 min. (B) 
TLC analysis of the reverse-hydrolysis reaction product. Lane 1, standard Galβ1-3GalNAc; lane 2, 
standard Glc; lane 3, Galβ1-3GalNAcα1-Glc produced by transglycosylation using EngBF; lane 4, 
purified reverse-hydrolysis reaction product of EngBF; lane 5, purified reverse-hydrolysis reaction 
product incubated with EngBF. (C) MALDI-TOF-MS analysis of the reverse-hydrolysis reaction 
product. The theoretical mass of Galβ1-3GalNAcα1-Glc is 545.49. 
 
 
 Table 1  Transglycosylation of Galβ1-3GalNAc to various peptides by EngBF 
 
 Peptide  Sequence a  Acceptor peptide        Transglycosylated peptide  
     RT b Mass   RT b Mass c   Observed mass d   Yield e 
 
 PAMP-12  FRKKWNKWALSR-NH2 54.8 1618.91  52.2 1984.24   1984.68 (M+H)+   4.4 
 PAMP-12(S11T) FRKKWNKWALTR-NH2  55.1 1632.93  52.5 1998.26   1999.08 (M+H)+   1.5 
 Bradykinin   RPPGFSPFR    58.0 1060.20  52.8 1425.53   1425.79 (M+H)+   0.47 
 MUC1a  AHGVTSAPDTR  31.1 1111.17  28.5 1476.50   1476.57 (M+H)+   2.4 
 Peptide T ASTTTNYT  31.0  857.87       28.5-29.8 f 1223.20   1245.54 (M+Na)+, 1261.62 (M+K)+ 9.7 
 
 a, Possible residues (Ser and Thr) for acceptor are underlined. 
 b, Retention times (min) of reversed phase HPLC under the condition described in Materials and method are shown. 
 c, Theoretical masses of glycopeptides attached with single disaccharide are shown. 
 d, Observed masses in MALDI-TOF-MS analyses are shown. 
 e, Yields (%) were calculated from the following formula: yield = peak area of transglycosylation product × 100 / peak areas of acceptor and transglycosylation product. 
 f, A single major peak and two minor peaks were observed. 
 




